Development and validation of an LC-MS/MS assay for the quantification of efavirenz in different biological matrices

Curley, Paul ORCID: 0000-0003-4596-2708, Siccardi, Marco ORCID: 0000-0002-3539-7867, Moss, Darren M and Owen, Andrew ORCID: 0000-0002-9819-7651 (2016) Development and validation of an LC-MS/MS assay for the quantification of efavirenz in different biological matrices. BIOANALYSIS, 8 (20). pp. 2125-2134.

Text EFV LC_MS Method_Bioanalysis.pdf - Author Accepted Manuscript Download (598kB)

Abstract

<h4>Aim</h4>The non-nucleoside reverse transcriptase inhibitor efavirenz is one of the most prescribed antiretroviral therapeutics. Efavirenz-containing therapy has become associated with the occurrence of CNS side effects, including sleep disturbances, depression and even psychosis.<h4>Results</h4>The investigation of efavirenz distribution required the development of a versatile and sensitive method. In addition to plasma, quantification was required in brain tissue and phosphate-buffered saline. The assay presented here was linear from 1.9 to 500 ng/ml. Accuracy and precision ranged between 93.7 and 99.5%, and 1.5 and 5.6%, respectively.<h4>Discussion</h4>The method developed here represents a versatile, sensitive and easy-to-use assay. The assay has been applied to in vitro and in vivo samples demonstrating reliable efavirenz quantification in multiple matrices.

Item Type:	Article
Uncontrolled Keywords:	brain tissue, efavirenz, LC-MS/MS, plasma, protein binding
Depositing User:	Symplectic Admin
Date Deposited:	06 Apr 2017 12:54
Last Modified:	19 Jan 2023 07:07
DOI:	10.4155/bio-2016-0021
Related URLs:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3006815